Tyrosine kinase inhibition: A therapeutic target for the management of chronic-phase chronic myeloid leukemia

Elias J. Jabbour, Jorge E. Cortes, Hagop M. Kantarjian

Research output: Contribution to journalReview article

16 Scopus citations

Abstract

Chronic myeloid leukemia (CML) is a hematologic neoplasm with a progressive, ultimately terminal, disease course. In most cases, CML arises owing to the aberrant formation of a chimeric gene for a constitutively active tyrosine kinase. Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. New tyrosine kinase inhibitors continue to improve the management of CML, offering alternative options for those resistant to or intolerant of standard tyrosine kinase inhibitors. Here we review the pathobiology of CML and explore emerging strategies to optimize the management of chronic-phase CML, particularly first-line treatment.

Original languageEnglish (US)
Pages (from-to)1433-1452
Number of pages20
JournalExpert Review of Anticancer Therapy
Volume13
Issue number12
DOIs
StatePublished - Nov 29 2013
Externally publishedYes

Keywords

  • Chronic myeloid leukemia
  • Molecular response
  • Suboptimal response
  • Tyrosine kinase inhibition

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tyrosine kinase inhibition: A therapeutic target for the management of chronic-phase chronic myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this